论文部分内容阅读
礼莱和艾米林制药公司向美国NDA提交了其拟肠促胰岛素的新药exenatide的申请。这是此类新型抗糖尿病药物的首次申请 ,期望 2 0 0 6年能在欧洲获得批准。此前欧洲糖尿病会议中公布了三组以改善血糖为目的的糖尿病治疗方案 (AMIGO)的研究资料。exenatide被申请用于治疗不能以二甲
Lilly and Emilen Pharmaceuticals filed an application for exenatide for its new intestine-stimulating hormone with the U.S. NDA. This is the first application for such a new antidiabetic drug and is expected to be approved in Europe in 2006. Prior to the European Diabetes Conference announced three groups to improve blood glucose for the purpose of diabetes treatment program (AMIGO) research data. Exenatide is being applied for treatment not with dimethyl